Empagliflozin (CAS 864070-44-0)
See product citations (5)
CAS Number:
864070-44-0
Purity:
≥98%
Molecular Weight:
450.91
Molecular Formula:
C23H27ClO7
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Empagliflozin is a compound extensively studied in biochemical and physiological research. It is primarily recognized for its role in inhibiting the sodium-glucose transport protein 2 (SGLT2), which is a key player in glucose reabsorption. This inhibition mechanism is of great interest in metabolic studies, as it provides insights into how the modulation of glucose reabsorption can affect overall glucose homeostasis in the body. Empagliflozin is also a focus in research related to energy metabolism and renal function. These research applications contribute substantially to our understanding of glucose handling in the body and have implications for the study of disorders related to glucose metabolism.
Empagliflozin (CAS 864070-44-0) References
- Sex-, Species-, and Tissue-Specific Metabolism of Empagliflozin in Male Mouse Kidney Forms an Unstable Hemiacetal Metabolite (M466/2) That Degrades to 4-Hydroxycrotonaldehyde, a Reactive and Cytotoxic Species. | Taub, ME., et al. 2015. Chem Res Toxicol. 28: 103-15. PMID: 25489797
- Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. | DeFronzo, RA., et al. 2015. Diabetes Care. 38: 384-93. PMID: 25583754
- [New SGLT2 inhibitor empagliflozin: modern and safe treatment of diabetes]. | Rušavý, Z. 2014. Vnitr Lek. 60: 926-7, 929-30. PMID: 25600037
- Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis. | Ojima, A., et al. 2015. Horm Metab Res. 47: 686-92. PMID: 25611208
- [Empagliflozin: another of silent revolutioners]. | Kvapil, M. 2014. Vnitr Lek. 60: 924-5. PMID: 25612346
- Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. | Lewin, A., et al. 2015. Diabetes Care. 38: 394-402. PMID: 25633662
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice. | Xu, L., et al. 2017. EBioMedicine. 20: 137-149. PMID: 28579299
- SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. | Li, C., et al. 2019. Cardiovasc Diabetol. 18: 15. PMID: 30710997
- Empagliflozin Attenuates Hyperuricemia by Upregulation of ABCG2 via AMPK/AKT/CREB Signaling Pathway in Type 2 Diabetic Mice. | Lu, YH., et al. 2020. Int J Biol Sci. 16: 529-542. PMID: 32015688
- Empagliflozin prevents doxorubicin-induced myocardial dysfunction. | Sabatino, J., et al. 2020. Cardiovasc Diabetol. 19: 66. PMID: 32414364
- Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis. | Nasiri-Ansari, N., et al. 2021. Int J Mol Sci. 22: PMID: 33467546
- Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin. | Philippaert, K., et al. 2021. Circulation. 143: 2188-2204. PMID: 33832341
- The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. | Quagliariello, V., et al. 2021. Cardiovasc Diabetol. 20: 150. PMID: 34301253
- Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway. | Cai, C., et al. 2022. Redox Biol. 52: 102288. PMID: 35325804
- Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis. | Zou, R., et al. 2022. Cardiovasc Diabetol. 21: 106. PMID: 35705980
Inhibitor of:
GLP-1R, Glucagon Receptor, Glut12, Insulin, KCC1, NaGLT1, Olr1646, Olr408, Pancreatic Icosapeptide, QRFP, Sg II, SGLT-1, SGLT-2, SGLT-5, SGLT-6, and SLU7.Activator of:
AGTRAP, MKP-4, MYL7, NaGLT1, and SGLT-3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Empagliflozin, 1 g | sc-482194 | 1 g | $156.00 | |||
Empagliflozin, 5 g | sc-482194A | 5 g | $312.00 | |||
Empagliflozin, 10 g | sc-482194B | 10 g | $399.00 | |||
Empagliflozin, 100 g | sc-482194C | 100 g | $1099.00 |